Previous close | 43.86 |
Open | 43.67 |
Bid | 37.04 x 100 |
Ask | 43.81 x 100 |
Day's range | 42.38 - 44.50 |
52-week range | 29.24 - 53.05 |
Volume | |
Avg. volume | 468,392 |
Market cap | 2.116B |
Beta (5Y monthly) | 1.73 |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
Full-Year 2023 Total Revenue Growth of 20% to $197.5 Million, with Adjusted EBITDA Growth of 40% Fourth Quarter Total Revenue Growth of 23% to $65.0 Million, with Adjusted EBITDA Growth of 50% Fourth Quarter Gross Margin of 75% and Adjusted EBITDA Margin of 34% Full-Year 2024 Total Revenue Guidance of $237 to $241 Million Conference Call Today at 8:30am Eastern Time CAMBRIDGE, Mass., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sport
CAMBRIDGE, Mass., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo, President and CEO and Joe Mara, CFO will participate in a fireside chat at the TD Cowen 44th Annual Health Care Conference at 11:10 a.m. ET on Tuesday, March 5, 2024. A webcast of the presentation will be available on the Investor Relations section of the Vericel Corporation website at: htt
CAMBRIDGE, Mass., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that it will report its fourth-quarter and full-year 2023 financial results on Thursday, February 29, 2024. Vericel’s management will host a conference call and webcast at 8:30 a.m. (ET) to discuss its financial results and business highlights. The live webcast can be accessed on the Investor Relations section